The REZOLV retrospective study (Retrospective Evaluation of Zubsolv Outcomes – A Longitudinal View) was completed as planned in August 2016. With 1,080 patients, the study is the largest retrospective study completed in the US aimed at optimizing the treatment of opioid dependence. Factors such as patient and prescriber characteristics, care settings, patient agreements and behavioral therapies have been studied.
The REZOLV study was a success with 978 of the 1,080 patients in total confirmed as being evaluable for treatment efficacy. From the patients evaluable for treatment, 77.6 percent (n=759) were determined to have been a treatment success, defined as a patient who completed 28 days of treatment and tested negative for opiates on the last follow-up drug screen.
The study results have generated an extensive amount of clinical data that Orexo will use in its dialogues with key stakeholders, including physicians, new and existing prescribers, politicians and payers, on how to advance the treatment of opioid dependence. The completion of the REZOLV study further strengthens Orexo’s position as the market player with the most substantial clinical database.